Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy

The effect of PF-05089771, a selective, peripherally restricted Nav1.7 sodium channel blocker on pain due to diabetic peripheral neuropathy was investigated in a randomised, placebo and active-controlled parallel group clinical trial (NCT02215252). A 1-week placebo-run in the period was followed by...

Full description

Bibliographic Details

Published in:	Pain (Amsterdam) Vol. 159; no. 8; p. 1465
Main Authors:	McDonnell, Aoibhinn, Collins, Susie, Ali, Zahid, Iavarone, Laura, Surujbally, Raulin, Kirby, Simon, Butt, Richard P
Format:	Journal Article
Language:	English
Published:	United States 01.08.2018
Subjects:	Adult Aged Diabetic Neuropathies - drug therapy Double-Blind Method Female Humans Male Middle Aged Neuralgia - drug therapy Phenyl Ethers - therapeutic use Pregabalin - therapeutic use Sodium Channel Blockers - therapeutic use Sulfonamides - therapeutic use Treatment Outcome
ISSN:	1872-6623, 1872-6623
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!